TRCT
SLN

Tower Research Capital (TRC)’s Silence Therapeutics SLN Stock Holding History

Tower Research Capital (TRC)’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2K Sell
2,313
-135
-6% -$743 ﹤0.01% 3806
2025
Q4 		$14.9K Buy
2,448
+1
+0% +$6 ﹤0.01% 3325
2025
Q3 		$12.7K Buy
2,447
+19
+0.8% +$106 ﹤0.01% 3759
2025
Q2 		$14.1K Buy
2,428
+61
+3% +$262 ﹤0.01% 3851
2025
Q1 		$6.67K Buy
2,367
+1,735
+275% +$8.47K ﹤0.01% 4023
2024
Q4 		$4.35K Buy
+632
New +$8.15K ﹤0.01% 4476
2024
Q1 		– Sell
-707
Closed -$12.3K – 6118
2023
Q4 		$12.3K Buy
+707
New +$7.94K ﹤0.01% 4057
2023
Q3 		– Sell
-800
Closed -$4.4K – 6194
2023
Q2 		$4.4K Buy
+800
New +$4.83K ﹤0.01% 4953
2022
Q3 		– Sell
-120
Closed -$1K – 6442
2022
Q2 		$1K Buy
120
+3
+3% +$36 ﹤0.01% 5850
2022
Q1 		$2K Buy
+117
New +$2.33K ﹤0.01% 5594

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Tower Research Capital (TRC)'s SLN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Silence Therapeutics (SLN) stake by 5.5% in Q1 2026, selling an estimated $743 and leaving 2,313 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3806.

Tower Research Capital (TRC) first reported a position in SLN in Q1 2022 and has held it in 10 quarters since. The position peaked at $14.9K in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Tower Research Capital (TRC) held 2,313 shares of Silence Therapeutics worth $12.2K as of Q1 2026.
  • Tower Research Capital (TRC) sold 135 Silence Therapeutics shares in Q1 2026, an estimated $743.
  • Silence Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3806 holding.
  • Tower Research Capital (TRC) first reported a position in Silence Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s Silence Therapeutics position peaked at $14.9K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.